EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Jeremy R Duvall iD, Joshua D Thomas iD, Raghida A Bukhalid, Kalli C Catcott iD, Keith W Bentley, Scott D Collins, Timothy Eitas, Brian D Jones, Eugene W Kelleher, Kelly Lancaster, Marina Protopopova, Soumya S Ray und 7 weitere

Journal of Medicinal Chemistry · 10.08.2023 · 66 (15) · 10715-10733

DOI: 10.1021/acs.jmedchem.3c00907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.07.2023. Verfasst von Jeremy R Duvall und 18 weiteren Autor:innen. Beteiligte Einrichtung: Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts 02139, United States. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While STING agonists have proven to be effective preclinically as anti-tumor agents, these promising results have yet to be translated in the clinic. A STING agonist antibody-drug conjugate (ADC) could overcome current limitations by improving tumor accessibility, allowing for systemic administration as well as tumor-localized activation of STING for greater anti-tumor activity and better tolerability. In line with this effort, a STING agonist ADC platform was identified through systematic optimization of the payload, linker, and scaffold based on multiple factors including potency and specificity in both in vitro and in vivo evaluations. The platform employs a potent non-cyclic dinucleotide STING agonist, a cleavable ester-based linker, and a hydrophilic PEG8-bisglucamine scaffold. A tumor-targeted ADC built with the resulting STING agonist platform induced robust and durable anti-tumor activity and demonstrated high stability and favorable pharmacokinetics in nonclinical species.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesAntineoplastic AgentsNeoplasmsHumansAntibodies, Monoclonal

Substanzen

ImmunoconjugatesAntibodies, MonoclonalAntineoplastic Agents

Autor:innen und Institutionen

  • Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • 3-Dimensional Consulting, 134 Franklin Avenue, Quincy, Massachusetts 02170, United States.

ORCID-Profile: Jeremy R Duvall, Joshua D Thomas, Kalli C Catcott

Zitieren

APA

Duvall, J. R., Thomas, J. D., Bukhalid, R. A., Catcott, K. C., Bentley, K. W., Collins, S. D., Eitas, T., Jones, B. D., Kelleher, E. W., Lancaster, K., Protopopova, M., Ray, S. S., Ter-Ovanesyan, E., Xu, L., Yang, L., Zurita, J., Damelin, M., Toader, D., & Lowinger, T. B. (2023). Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates. Journal of Medicinal Chemistry, 66(15), 10715-10733. https://doi.org/10.1021/acs.jmedchem.3c00907

Vancouver

Duvall JR, Thomas JD, Bukhalid RA, Catcott KC, Bentley KW, Collins SD, et al. Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates. Journal of Medicinal Chemistry. 2023;66(15):10715-10733. doi:10.1021/acs.jmedchem.3c00907

BibTeX
@article{Duvall2023,
  author = {Duvall, Jeremy R and Thomas, Joshua D and Bukhalid, Raghida A and Catcott, Kalli C and Bentley, Keith W and Collins, Scott D and Eitas, Timothy and Jones, Brian D and Kelleher, Eugene W and Lancaster, Kelly and Protopopova, Marina and Ray, Soumya S and Ter-Ovanesyan, Elena and Xu, Ling and Yang, Liping and Zurita, Jeffrey and Damelin, Marc and Toader, Dorin and Lowinger, Timothy B},
  title = {Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {15},
  pages = {10715--10733},
  doi = {10.1021/acs.jmedchem.3c00907}
}
Kostenlos starten →